The Food and Drug Administration has approved Moderna’s mFlusiva, making it the first influenza vaccine in the United States produced using the same messenger RNA technology that became widely known during the COVID-19 pandemic.
The new vaccine is intended for adults 50 and older. Moderna, which is headquartered in Cambridge, Massachusetts, said some doses are expected to become available soon through select retailers. The announcement comes as other flu vaccine brands are already beginning to reach pharmacies ahead of the fall vaccination season.
Americans already have several influenza vaccines available, including three options specifically recommended for people 65 and older. Even with those vaccines, influenza continues to kill tens of thousands of people in the United States during some seasons, with older adults among those facing the greatest risk of severe illness and complications.
Seasonal flu vaccines have to be reformulated every year so they can more closely match the influenza strains expected to circulate. Messenger RNA vaccines can be manufactured more quickly than many traditional vaccine types, giving health officials another potential tool if rapidly changing flu viruses force manufacturers to produce updated doses on a shorter timeline.
For adults between 50 and 64 years old, the FDA granted mFlusiva full approval. Moderna supported that portion of its application with a study involving roughly 40,000 participants. Results showed that people receiving the mRNA vaccine experienced approximately 27% fewer influenza cases than participants who received another commonly used flu vaccine.
The regulatory pathway was different for adults 65 and older. For that age group, the FDA granted accelerated approval after a smaller study showed that mFlusiva produced a strong immune response when compared with an existing high-dose influenza vaccine designed for older adults. Moderna is required to conduct an additional study as part of that approval process.
Moderna’s clinical data did not reveal major safety concerns. Temporary reactions were reported, including pain where the vaccine was injected, fever, headache, fatigue and body aches. Those reactions occurred somewhat more frequently among mFlusiva recipients than among people who received current flu vaccines.
The approval follows an unusual disagreement between Moderna and federal regulators earlier in 2026. A senior FDA official initially blocked the company’s application as the agency increased its scrutiny of vaccines under Health and Human Services Secretary Robert F. Kennedy Jr.
Moderna publicly challenged that decision, and the FDA reversed course several days later, allowing the application to move forward under a revised regulatory approach. In June, an independent FDA advisory committee then voted unanimously in favor of recommending approval of the vaccine.
The approval adds another vaccine option for older adults as the United States prepares for the 2026-2027 influenza season while also marking the first time mRNA technology has been cleared for use in a seasonal flu vaccine.
Source: Arizona’s Family



